Moleculin Total Assets from 2010 to 2025

MBRX Stock

USD 2.18 0.91 71.65%

Moleculin Biotech Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 35.4 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2015-09-30

Previous Quarter

25.6 M

Current Value

23.4 M

Quarterly Volatility

26.4 M

Yuan Drop

Covid

Check Moleculin Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moleculin Biotech's main balance sheet or income statement drivers, such as Interest Income of 965.1 K, Depreciation And Amortization of 108.6 K or Interest Expense of 2.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.92. Moleculin financial statements analysis is a perfect complement when working with Moleculin Biotech Valuation or Volatility modules.

Check out the analysis of Moleculin Biotech Correlation against competitors.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Latest Moleculin Biotech's Total Assets Growth Pattern

Below is the plot of the Total Assets of Moleculin Biotech over the last few years. Total assets refers to the total amount of Moleculin Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Moleculin Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Moleculin Biotech's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moleculin Biotech's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 38.22 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Moleculin Total Assets Regression Statistics

	Arithmetic Mean	23,059,713
	Geometric Mean	2,307,515
	Coefficient Of Variation	106.32
	Mean Deviation	18,988,492
	Median	19,585,000
	Standard Deviation	24,516,456
	Sample Variance	601.1T
	Range	84.1M
	R-Value	0.80
	Mean Square Error	232.8T
	R-Squared	0.64
	Significance	0.0002
	Slope	4,114,673
	Total Sum of Squares	9015.8T

Moleculin Total Assets History

	2025	35.4 M
	2024	43.9 M
	2023	38.2 M
	2022	57.4 M
	2021	84.1 M
	2020	29 M
	2019	25.2 M

Other Fundumenentals of Moleculin Biotech

Intangibles To Total Assets

Moleculin Biotech Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Capital Surpluse	Intangible Assets	Property Plant Equipment	Net Invested Capital	Net Working Capital	Net Receivables	Capital Stock
Total Assets		0.99	0.81	0.76	-0.97	-0.77	0.72	0.57	-0.76	0.98	-0.81	0.57	0.86	0.27	0.7	0.88	0.92	0.03	0.1
Total Stockholder Equity	0.99		0.77	0.67	-0.99	-0.68	0.6	0.44	-0.68	0.99	-0.71	0.45	0.76	0.2	0.59	0.93	0.95	0.0	0.0
Net Tangible Assets	0.81	0.77		0.67	-0.76	-0.94	0.76	0.71	-0.6	0.8	-0.7	0.4	0.77	0.62	0.55	0.72	0.75	0.52	-0.13
Current Deferred Revenue	0.76	0.67	0.67		-0.62	-0.79	0.84	0.81	-0.85	0.66	-0.79	0.81	0.85	0.4	0.85	0.43	0.51	0.1	0.33
Net Debt	-0.97	-0.99	-0.76	-0.62		0.67	-0.56	-0.4	0.58	-0.99	0.69	-0.42	-0.75	-0.14	-0.57	-0.96	-0.98	0.02	-0.01
Retained Earnings	-0.77	-0.68	-0.94	-0.79	0.67		-0.89	-0.87	0.7	-0.72	0.82	-0.63	-0.89	-0.57	-0.74	-0.55	-0.61	-0.41	-0.14
Accounts Payable	0.72	0.6	0.76	0.84	-0.56	-0.89		0.84	-0.78	0.63	-0.86	0.69	0.9	0.51	0.82	0.39	0.47	0.23	0.19
Total Liab	0.57	0.44	0.71	0.81	-0.4	-0.87	0.84		-0.72	0.47	-0.82	0.82	0.81	0.65	0.84	0.23	0.34	0.34	0.44
Short Long Term Debt	-0.76	-0.68	-0.6	-0.85	0.58	0.7	-0.78	-0.72		-0.62	0.81	-0.76	-0.77	-0.35	-0.76	-0.38	-0.45	-0.07	-0.29
Total Current Assets	0.98	0.99	0.8	0.66	-0.99	-0.72	0.63	0.47	-0.62		-0.73	0.47	0.8	0.23	0.61	0.95	0.97	0.02	0.03
Short Term Debt	-0.81	-0.71	-0.7	-0.79	0.69	0.82	-0.86	-0.82	0.81	-0.73		-0.81	-0.9	-0.35	-0.94	-0.51	-0.6	-0.01	-0.4
Common Stock	0.57	0.45	0.4	0.81	-0.42	-0.63	0.69	0.82	-0.76	0.47	-0.81		0.81	0.26	0.93	0.2	0.32	-0.22	0.79
Capital Surpluse	0.86	0.76	0.77	0.85	-0.75	-0.89	0.9	0.81	-0.77	0.8	-0.9	0.81		0.41	0.89	0.59	0.67	0.04	0.39
Intangible Assets	0.27	0.2	0.62	0.4	-0.14	-0.57	0.51	0.65	-0.35	0.23	-0.35	0.26	0.41		0.31	0.14	0.17	0.7	-0.1
Property Plant Equipment	0.7	0.59	0.55	0.85	-0.57	-0.74	0.82	0.84	-0.76	0.61	-0.94	0.93	0.89	0.31		0.37	0.48	-0.12	0.6
Net Invested Capital	0.88	0.93	0.72	0.43	-0.96	-0.55	0.39	0.23	-0.38	0.95	-0.51	0.2	0.59	0.14	0.37		0.99	0.03	-0.16
Net Working Capital	0.92	0.95	0.75	0.51	-0.98	-0.61	0.47	0.34	-0.45	0.97	-0.6	0.32	0.67	0.17	0.48	0.99		0.01	-0.05
Net Receivables	0.03	0.0	0.52	0.1	0.02	-0.41	0.23	0.34	-0.07	0.02	-0.01	-0.22	0.04	0.7	-0.12	0.03	0.01		-0.53
Capital Stock	0.1	0.0	-0.13	0.33	-0.01	-0.14	0.19	0.44	-0.29	0.03	-0.4	0.79	0.39	-0.1	0.6	-0.16	-0.05	-0.53

Click cells to compare fundamentals

About Moleculin Biotech Financial Statements

Moleculin Biotech investors use historical fundamental indicators, such as Moleculin Biotech's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Moleculin Biotech. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	43.9 M	35.4 M
Intangibles To Total Assets	0.34	0.45

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC